Mineralys Therapeutics, Inc. (MLYS)
| Market Cap | 1.42B -51.9% |
| Revenue (ttm) | n/a |
| Net Income | -369.97M |
| EPS | -4.38 |
| Shares Out | 88.56M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 738,340 |
| Open | 15.66 |
| Previous Close | 15.52 |
| Day's Range | 15.25 - 16.11 |
| 52-Week Range | 14.91 - 47.65 |
| Beta | 0.83 |
| Analysts | Strong Buy |
| Price Target | 43.56 (+171.83%) |
| Earnings Date | Nov 4, 2026 |
About MLYS
Mineralys Therapeutics, Inc., a biopharmaceutical company, develops medicines to target diseases driven by dysregulated aldosterone in the United States. It is developing lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by dysregulated aldosterone, such as hypertension, chronic kidney disease, and obstructive sleep apnea. The company was formerly known as Catalys SC1, Inc. and changed its name to Mineralys Therapeutics, Inc. in May 2020. Minera... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 11 analysts, the average rating for MLYS stock is "Strong Buy." The 12-month stock price target is $43.56, which is an increase of 171.83% from the latest price.
News
Mineralys Therapeutics Transcript: 3rd Annual Guggenheim Healthcare Innovation Conference
Lorundrostat’s Dec. 22, 2026 PDUFA date sets up a targeted 2027 launch, focused on patients uncontrolled on multiple therapies. Management cited broad clinical data, plans for Medicare access and funding into 2028, while considering further studies and partnering.
Mineralys Therapeutics announces long-term results from Transform-HTN trial
Mineralys Therapeutics (MLYS) announced long-term results from the Transform-HTN open-label extension trial of lorundrostat in participants with uncontrolled or resistant hypertension, demonstrating s...
Mineralys Therapeutics Presents New Late-Breaking Data from Transform-HTN Open-Label Extension Trial of Lorundrostat in Hypertension at AHA Scientific Sessions 2026
– In the largest long-term hypertension trial of an aldosterone synthase inhibitor to date, lorundrostat demonstrated sustained reduction in automated office systolic blood pressure (AOSBP) of 17.8 mm...
Mineralys Therapeutics price target lowered to $19 from $29 at UBS
UBS lowered the firm’s price target on Mineralys Therapeutics (MLYS) to $19 from $29 and keeps a Neutral rating on the shares.
Mineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
RADNOR, Pa., Nov. 06, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and aldosterone-related a...
Mineralys Therapeutics Earnings Call Transcript: Q3 2026
Lorundrostat’s December PDUFA target is approaching, with launch preparations and payer engagement advancing. Q3 net loss widened to $57.3M, while $624.7M in cash and investments was expected to fund operations into 2028.
Mineralys Therapeutics Earnings release: Q3 2026
Mineralys Therapeutics released its Q3 2026 earnings on November 4, 2026, summarizing the period's financial results.
Mineralys Therapeutics Quarterly report: Q3 2026
Mineralys Therapeutics has published its Q3 2026 quarterly earnings report on November 4, 2026.
Mineralys Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update
– Commercialization plans for lorundrostat are on track ahead of PDUFA target date of December 22, 2026 – – New analyses from the pivotal Launch-HTN trial showed 46% of participants with uncontrolled ...
Mineralys Therapeutics Slides: Corporate presentation
Mineralys Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on November 4, 2026.
Mineralys Therapeutics to Participate in Upcoming Investor Conferences
RADNOR, Pa., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and aldosterone-related a...
Mineralys Therapeutics to Announce Third Quarter 2026 Financial Results and Host Conference Call on Wednesday, November 4, 2026
RADNOR, Pa., Oct. 28, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and aldosterone-related a...
Mineralys Therapeutics announces full results from Explore-CKD trial
Mineralys Therapeutics (MLYS) announced that the full results from the Phase 2 Explore-CKD trial of lorundrostat in participants with uncontrolled hypertension, CKD and albuminuria have been published...
Mineralys Therapeutics Announces Publication of Phase 2 Explore-CKD Trial Results for Lorundrostat in Kidney International
- Explore-CKD met its primary endpoint; lorundrostat 25 mg once daily added to an SGLT2 inhibitor achieved a statistically significant reduction in systolic blood pressure at four weeks -
Mineralys Therapeutics Presents New Lorundrostat Data in Participants with Hypertension and Chronic Kidney Disease at ASN Kidney Week 2026
In the large, pivotal Phase 3 Launch-HTN trial, lorundrostat achieved similar significant blood pressure reductions in participants with and without CKD, with consistent reductions across Stages 1-3 C...
Mineralys Therapeutics Expands its Board of Directors with the Appointments of Kristine Peterson and Lonnel Coats
RADNOR, Pa., Oct. 19, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and aldosterone-related a...
Mineralys Therapeutics initiated with a Neutral at UBS
UBS initiated coverage of Mineralys Therapeutics (MLYS) with a Neutral rating and $29 price target The company’s lorundrostat, an aldosterone synthase inhibitor for later-line hypertension, is positio...
Mineralys Therapeutics presents new analysis from Launch-HTN trial
Mineralys Therapeutics (MLYS) announced the presentation of a new analysis from its pivotal Phase 3 Launch-HTN trial, showing that at Week 12, 46% of lorundrostat-treated participants achieved the AHA...
Mineralys Therapeutics Presents New Data for Lorundrostat at the American Heart Association Hypertension Scientific Sessions 2026
- New analyses from the pivotal Launch-HTN trial showed that 46% of participants with difficult-to-treat hypertension receiving lorundrostat 50 mg achieved the AHA/ACC Guideline systolic blood pressur...
Mineralys Therapeutics Announces Presentation of New Lorundrostat Data at the American Society of Nephrology (ASN) Kidney Week 2026
RADNOR, Pa., Oct. 02, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and aldosterone-related a...
Mineralys Therapeutics Announces Presentation of Lorundrostat Data at American Heart Association Hypertension Scientific Sessions 2026
RADNOR, Pa., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and aldosterone-related a...
Mineralys Therapeutics Transcript: Stifel 2026 Virtual Cardiometabolic Forum
Aldosterone synthase inhibitors are reshaping hypertension treatment, with lorundrostat poised for launch following robust phase III data and strong payer interest. Commercial plans target both specialist and primary care channels, with initial access in fourth-line therapy and expansion expected.
Mineralys Therapeutics to Participate in the Stifel 2026 Virtual Cardiometabolic Forum
RADNOR, Pa., Sept. 24, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and aldosterone-related ...
Mineralys Therapeutics' Transform-HTN Open-Label Extension Trial Data Selected for Late-Breaking Presentation at American Heart Association Scientific Sessions 2026
RADNOR, Pa., Sept. 23, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and aldosterone-related ...
Mineralys Therapeutics Transcript: Wells Fargo 21st Annual Healthcare Conference
Lorundrostat is advancing toward a December PDUFA date, supported by robust clinical data and a comprehensive commercial build-out targeting third- and fourth-line hypertension. The launch strategy emphasizes parity access, broad prescriber reach, and ongoing R&D, with full funding secured through 2028.